Stolper Co Sells 199 Shares of Johnson & Johnson $JNJ

Stolper Co lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 34,016 shares of the company’s stock after selling 199 shares during the period. Johnson & Johnson comprises approximately 1.7% of Stolper Co’s holdings, making the stock its 22nd largest position. Stolper Co’s holdings in Johnson & Johnson were worth $5,196,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Highline Wealth Partners LLC boosted its holdings in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at about $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson during the 1st quarter valued at about $52,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on JNJ shares. JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Barclays increased their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Bank of America increased their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Thursday, July 17th. Finally, Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $177.87.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.0%

Shares of NYSE JNJ opened at $175.97 on Friday. The firm has a 50-day simple moving average of $172.80 and a two-hundred day simple moving average of $161.69. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The company has a market cap of $423.80 billion, a P/E ratio of 18.82, a PEG ratio of 2.22 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the firm posted $2.82 earnings per share. The company’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.